Guggenheim Raises InflaRx (NASDAQ:IFRX) Price Target to $10.00

InflaRx (NASDAQ:IFRX) had its price objective lifted by equities research analysts at Guggenheim from $7.00 to $10.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Stock Performance

Shares of NASDAQ:IFRX opened at $1.32 on Wednesday. InflaRx has a 1 year low of $1.13 and a 1 year high of $2.82. The stock has a 50-day simple moving average of $1.90 and a 200-day simple moving average of $1.90. The stock has a market capitalization of $88.55 million, a P/E ratio of -1.23 and a beta of 1.98.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. Analysts predict that InflaRx will post -1.04 earnings per share for the current year.

Institutional Trading of InflaRx

Hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC acquired a new stake in shares of InflaRx during the fourth quarter worth $55,000. Northern Trust Corp raised its stake in InflaRx by 1,933.1% during the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock valued at $1,647,000 after acquiring an additional 634,045 shares in the last quarter. Two Sigma Securities LLC acquired a new position in shares of InflaRx during the fourth quarter valued at $28,000. Walleye Capital LLC bought a new stake in shares of InflaRx during the 4th quarter worth about $51,000. Finally, Raymond James Financial Inc. bought a new stake in InflaRx during the fourth quarter worth approximately $1,576,000. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.